127 related articles for article (PubMed ID: 8929969)
1. Sex difference in 5HT2 receptor in the living human brain.
Biver F; Lotstra F; Monclus M; Wikler D; Damhaut P; Mendlewicz J; Goldman S
Neurosci Lett; 1996 Feb; 204(1-2):25-8. PubMed ID: 8929969
[TBL] [Abstract][Full Text] [Related]
2. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.
Sadzot B; Lemaire C; Maquet P; Salmon E; Plenevaux A; Degueldre C; Hermanne JP; Guillaume M; Cantineau R; Comar D
J Cereb Blood Flow Metab; 1995 Sep; 15(5):787-97. PubMed ID: 7673371
[TBL] [Abstract][Full Text] [Related]
3. Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.
Smith GS; Price JC; Lopresti BJ; Huang Y; Simpson N; Holt D; Mason NS; Meltzer CC; Sweet RA; Nichols T; Sashin D; Mathis CA
Synapse; 1998 Dec; 30(4):380-92. PubMed ID: 9826230
[TBL] [Abstract][Full Text] [Related]
4. In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: a film and electronic autoradiographic study.
Biver F; Lotstra F; Monclus M; Dethy S; Damhaut P; Wikler D; Luxen A; Goldman S
Nucl Med Biol; 1997 May; 24(4):357-60. PubMed ID: 9257335
[TBL] [Abstract][Full Text] [Related]
5. Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man.
Larisch R; Klimke A; Hamacher K; Henning U; Estalji S; Hohlfeld T; Vosberg H; Tosch M; Gaebel W; Coenen HH; Müller-Gärtner HW
Behav Brain Res; 2003 Feb; 139(1-2):21-9. PubMed ID: 12642173
[TBL] [Abstract][Full Text] [Related]
6. Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder.
Larisch R; Klimke A; Mayoral F; Hamacher K; Herzog HR; Vosberg H; Tosch M; Gaebel W; Rivas F; Coenen HH; Müller-Gärtner HW
Nuklearmedizin; 2001 Aug; 40(4):129-34. PubMed ID: 11556203
[TBL] [Abstract][Full Text] [Related]
7. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.
Biver F; Goldman S; Luxen A; Monclus M; Forestini M; Mendlewicz J; Lotstra F
Eur J Nucl Med; 1994 Sep; 21(9):937-46. PubMed ID: 7995287
[TBL] [Abstract][Full Text] [Related]
8. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging.
Rosier A; Dupont P; Peuskens J; Bormans G; Vandenberghe R; Maes M; de Groot T; Schiepers C; Verbruggen A; Mortelmans L
Psychiatry Res; 1996 Nov; 68(1):11-22. PubMed ID: 9027929
[TBL] [Abstract][Full Text] [Related]
9. Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans.
Price JC; Lopresti BJ; Meltzer CC; Smith GS; Mason NS; Huang Y; Holt DP; Gunn RN; Mathis CA
Synapse; 2001 Jul; 41(1):11-21. PubMed ID: 11354009
[TBL] [Abstract][Full Text] [Related]
10. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.
Tan PZ; Baldwin RM; Van Dyck CH; Al-Tikriti M; Roth B; Khan N; Charney DS; Innis RB
Nucl Med Biol; 1999 Aug; 26(6):601-8. PubMed ID: 10587097
[TBL] [Abstract][Full Text] [Related]
11. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.
Meltzer CC; Price JC; Mathis CA; Greer PJ; Cantwell MN; Houck PR; Mulsant BH; Ben-Eliezer D; Lopresti B; DeKosky ST; Reynolds CF
Am J Psychiatry; 1999 Dec; 156(12):1871-8. PubMed ID: 10588399
[TBL] [Abstract][Full Text] [Related]
12. Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem.
Forutan F; Estalji S; Beu M; Nikolaus S; Hamacher K; Coenen HH; Vosberg H; Müller-Gärtner HW; Larisch R
Nuklearmedizin; 2002; 41(4):197-201. PubMed ID: 12224404
[TBL] [Abstract][Full Text] [Related]
13. Central serotonergic S2 binding in Papio anubis measured in vivo with N-omega-[18F]fluoroethylketanserin and PET.
Moerlein SM; Perlmutter JS
Neurosci Lett; 1991 Feb; 123(1):23-6. PubMed ID: 2062450
[TBL] [Abstract][Full Text] [Related]
14. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.
Pinborg LH; Adams KH; Svarer C; Holm S; Hasselbalch SG; Haugbøl S; Madsen J; Knudsen GM
J Cereb Blood Flow Metab; 2003 Aug; 23(8):985-96. PubMed ID: 12902843
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats.
Lemaire C; Cantineau R; Guillaume M; Plenevaux A; Christiaens L
J Nucl Med; 1991 Dec; 32(12):2266-72. PubMed ID: 1744713
[TBL] [Abstract][Full Text] [Related]
16. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin.
van Dyck CH; Tan PZ; Baldwin RM; Amici LA; Garg PK; Ng CK; Soufer R; Charney DS; Innis RB
J Nucl Med; 2000 Feb; 41(2):234-41. PubMed ID: 10688105
[TBL] [Abstract][Full Text] [Related]
17. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.
Bailer UF; Price JC; Meltzer CC; Mathis CA; Frank GK; Weissfeld L; McConaha CW; Henry SE; Brooks-Achenbach S; Barbarich NC; Kaye WH
Neuropsychopharmacology; 2004 Jun; 29(6):1143-55. PubMed ID: 15054474
[TBL] [Abstract][Full Text] [Related]
18. Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies.
Staley JK; Van Dyck CH; Tan PZ; Al Tikriti M; Ramsby Q; Klump H; Ng C; Garg P; Soufer R; Baldwin RM; Innis RB
Nucl Med Biol; 2001 Apr; 28(3):271-9. PubMed ID: 11323237
[TBL] [Abstract][Full Text] [Related]
19. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.
Quednow BB; Treyer V; Hasler F; Dörig N; Wyss MT; Burger C; Rentsch KM; Westera G; Schubiger PA; Buck A; Vollenweider FX
Neuroimage; 2012 Feb; 59(4):3922-32. PubMed ID: 21996132
[TBL] [Abstract][Full Text] [Related]
20. Estimation of brain 5HT2 receptor binding potential with a single-dose PET paradigm.
Petit Taboué MC; Baron JC
Eur J Nucl Med; 1995 Jun; 22(6):585-6. PubMed ID: 7556308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
